Anti-C3A monoclonal antibody
Latest Information Update: 17 Dec 2003
At a glance
- Originator Human Genome Sciences
- Class Monoclonal antibodies
- Mechanism of Action Complement C3a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 17 Dec 2003 No development reported - Preclinical for Asthma in USA (unspecified route)
- 20 Jul 2001 Preclinical development for Asthma in USA (Unknown route)